胸腺五肽联合常规抗结核药物治疗耐多药结核病患者的效果

Effects of Thymopentin combined with conventional anti-tuberculosis drugs in treatment of patients with multidrug-resistant tuberculosis

目的:观察胸腺五肽联合常规抗结核药物治疗耐多药结核病(MDR-TB)患者的效果。方法:选取100例MDR-TB患者为研究对象,按随机抽签法分为对照组和研究组各50例。对照组采用常规抗结核药物治疗,研究组采用胸腺五肽联合常规抗结核药物治疗。比较两组疗效、痰菌转阴率和治疗前后T细胞亚群水平。结果:研究组治疗总有效率为88.0%,高于对照组的72.0%,差异有统计学意义(P<0.05);研究组痰菌转阴率为82.0%,高于对照组的64.0%,差异有统计学意义(P<0.05);治疗后,研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05)。结论:胸腺五肽联合常规抗结核药物治疗MDR-TB患者可提高治疗总有效率、痰菌转阴率和T细胞亚群水平,其效果优于单纯常规抗结核药物。

Objective: To observe effects of Thymopentin combined with conventional anti-tuberculosis drugs in treatment of patients with multidrug-resistant tuberculosis(MDR-TB). Methods: 100 MDR-TB patients were selected as the research objects, and were divided into control group and study group according to the random drawing method, 50 cases in each. The control group was treated with the conventional antituberculosis drugs, while the study group was treated with Thymopentin combined with the conventional anti-tuberculosis drugs. The curative effects, sputum conversion rate and T cell subgroup index levels before and after the treatment were compared between the two groups. Results: The total effective rate of treatment in the study group was 88.0%, which was higher than 72.0% in the control group, and the difference was statistically significant(P<0.05). The sputum negative conversion rate in the study group was 82.0%, which was higher than the control group of 64.0%, and the difference was statistically significant(P<0.05). After the treatment, the levels of CD3^(+), CD4^(+) and CD4^(+)/CD8^(+) in the study group were higher than those in the control group, and the differences were statistically significant(P<0.05). Conclusions: Thymopentin combined with the conventional antituberculosis drugs in the treatment of the MDR-TB patients can improve the total effective rate of treatment, the sputum negative conversion rate and the T cell subset index levels. Moreover, it is superior to single conventional anti-tuberculosis drugs.